SPHDF (Santhera Pharmaceuticals Holding AG) Shares Outstanding (EOP): 13.39 Mil (As of Dec. 2025)


SPHDF Santhera Pharmaceuticals Holding AG SPHDF
39 GF Score
Price $23.25
GF Value $24.73
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Shares Outstanding (EOP)?

Santhera Pharmaceuticals Holding AG SPHDF 39 Shares Outstanding (EOP) is 13.39 Mil as of Dec. 2025. GuruFocus rates SPHDF with a GF Score™ of 39/100 and a GF Value™ of $24.73 (Fairly Valued). The stock has 7 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Santhera Pharmaceuticals Holding AG's shares outstanding for the quarter that ended in Dec. 2025 was 13.39 Mil.

Santhera Pharmaceuticals Holding AG's quarterly shares outstanding increased from Jun. 2025 (12.95 Mil) to Dec. 2025 (13.39 Mil). It means Santhera Pharmaceuticals Holding AG issued new shares from Jun. 2025 to Dec. 2025 .

Santhera Pharmaceuticals Holding AG's annual shares outstanding increased from Dec. 2024 (12.79 Mil) to Dec. 2025 (13.39 Mil). It means Santhera Pharmaceuticals Holding AG issued new shares from Dec. 2024 to Dec. 2025 .


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Santhera Pharmaceuticals Holding AG Shares Outstanding (EOP) Related Terms


Santhera Pharmaceuticals Holding AG Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG Shares Outstanding (EOP) Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.96 6.59 11.32 12.79 13.39

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.32 11.70 12.79 12.95 13.39

SPHDF vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP) falls into.


SPHDF
39GF Score
Santhera Pharmaceuticals Holding AG SPHDF
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 13.39 Mil mean?
Santhera Pharmaceuticals Holding AG (SPHDF) has a Shares Outstanding (EOP) of 13.39 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Santhera Pharmaceuticals Holding AG and its competitors.
Is Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP) too high?
Santhera Pharmaceuticals Holding AG's current Shares Outstanding (EOP) is 13.39 Mil. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP) compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's Shares Outstanding (EOP) of 13.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current Shares Outstanding (EOP) is 13.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current Shares Outstanding (EOP) is 13.39 Mil. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current Shares Outstanding (EOP) is 13.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.

Key valuation signals for SPHDF:

  • Shares Outstanding (EOP): 13.39 Mil
  • GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for SPHDF

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.25
Price
$24.73
GF Value